Метаболически-ассоциированная жировая болезнь печени (МАЖБП) как фактор риска развития злокачественных новообразований

Целью данного обзора стала актуализация информации по распространенности и взаимосвязи развития рака различных локализаций с неалкогольной, метаболически-ассоциированной жировой болезнью печени (НАЖБП/МАЖБП). Обсуждение: второй по распространенности причиной смерти среди пациентов с НАЖБП являются злокачественные новообразования как органов пищеварения (печень, толстая кишка, пищевод, желудок и поджелудочная железа), так и других локализаций (почки, предстательная железа у мужчин и молочная железа у женщин). Ожирение и ассоциированные с ним метаболические нарушения связаны с увеличением заболеваемости или смертности от разных видов рака. Ввиду высокой распространенности НАЖБП среди пациентов с метаболическим синдромом, сахарным диабетом 2 типа, предполагается экстраполяция подобного развития и среди пациентов с НАЖБП. Метаболические нарушения, дисбаланс микрофлоры кишечника рассматриваются как возможные патогенетические механизмы увеличения риска рака среди пациентов, страдающих НАЖБП. Заключение: помимо риска развития гепатоцеллюлярной карциномы как естественного течения заболевания, накапливаются убедительные доказательства роли НАЖБП в качестве независимого фактора риска развития и прогрессирования рака, особенно в желудочно-кишечном тракте.

неалкогольная жирования болезнь печени, метаболически-ассоциированная болезнь, рак, адипокины, микробиота кишечника

1. Younossi Z.M., Stepanova M., Younossi Y. et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020;69(3):564-568. https://doi.org/10.1136/gutjnl-2019-318813.

2. Ivashkin V.T., Drapkina O. M., Maev I. V., Truhmanov A. S., Blinov D.V, Pal’gova L.K., Cukanov V. V., Ushakova T. I. [The prevalence of non-alcoholic fatty liver disease in outpatients in the Russian Federation: results of the DIREG 2 study]. RZhGGK. 2015;6:31-41. (in Russ.)@@ Ивашкин В. Т., Драпкина О. М., Маев И. В., Трухманов А. С., Блинов Д.В, Пальгова Л. К., Цуканов В. В., Ушакова Т. И. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. РЖГГК. 2015;6:31-41.

3. Paik J.M., Kabbara K., Eberly K. E. et al. Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology. 2022;75(5):1204-1217. https://doi.org/10.1002/hep.32228.

4. Krolevets T. S., Livzan M. A. Non-alcoholic fatty liver disease: digest 2021.Russian Journal of Evidence-Based Gastroenterology. 2021;10(2):27-35. (In Russ.) https://doi.org/10.17116/dokgastro20211002127.@@ Кролевец Т. С., Ливзан М. А. Неалкогольная жировая болезнь печени: дайджест 2021. Доказательная гастроэнтерология. 2021;10(2):27-35. https://doi.org/10.17116/dokgastro20211002127.

5. Maevskaya M.V., Kotovskaya Yu.V., Ivashkin V. T. et al. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(2). https://doi.org/10.26442/00403660.2022.02.201363.@@ Маевская М. В., Котовская Ю. В., Ивашкин В. Т. и соавт. Национальный Консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022;94(2). https://doi.org/10.26442/00403660.2022.02.201363.

6. Targher G., Byrne C. D., Lonardo A. et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589-600. https://doi.org/10.1016/j.jhep.2016.05.013.

7. Tilg H., Moschen A. R. Mechanisms behind the link between obesity and gastrointestinal cancers. Best Pract. Res. Clin. Gastroenterol. 2014;28:599-610. https://doi.org/10.1016/j.bpg.2014.07.006.

8. Kim G.A., Lee H. C., Choe J. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol. 2017 https://doi.org/10.1016/j.jhep.2017.09.012.

9. Paternostro R, Sieghart W, Trauner M, Pinter M. Cancer and hepatic steatosis. ESMO Open. 2021;6(4):100185. https://doi.org/10.1016/j.esmoop.2021.100185.

10. Scalera A., Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol. 2014;20(28):9217-9228. https://doi.org/10.3748/wjg.v20.i28.9217.

11. Hwang S.T., Cho Y. K., Park J. H. et al. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J. Gastroenterol. Hepatol. 2010;25:562-567. https://doi.org/10.1111/j.1440-1746.2009.06117.x.

12. Lee Y.I., Lim Y.-S., Park H. S. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: A retrospective cohort study. J. Gastroenterol. Hepatol. 2012;27:91-95. https://doi.org/10.1111/j.1440-1746.2011.06816.x.

13. Wong V.W.-S., Wong G. L.-H., Tsang S. W.-C. et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut. 2011;60:829-836. https://doi.org/10.1136/gut.2011.237974.

14. Stadlmayr A., Aigner E., Steger B., et al. Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia. J Intern Med. 2011;270(1):41-49. https://doi.org/10.1111/j.1365-2796.2011.02377.x.

15. Huang K.W., Leu H. B., Wang Y. J., et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal Dis. 2013;15(7):830-835. https://doi.org/10.1111/codi.12172.

16. Botteri E., Peveri G., Berstad P. et al. Changes in Lifestyle and Risk of Colorectal Cancer in the European Prospective Investigation Into Cancer and Nutrition. Am J Gastroenterol. 2022;10.14309/ajg.0000000000002065. https://doi.org/10.14309/ajg.0000000000002065.

17. Esposito K., Chiodini P., Colao A. et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402-2411. https://doi.org/10.2337/dc12-0336.

18. Bjørge T., Lukanova A., Tretli S. et al. Metabolic risk factors and ovarian cancer in the Metabolic Syndrome and Cancer project.Int J Epidemiol. 2011;40(6):1667-1677. https://doi.org/10.1093/ije/dyr130.

19. Harvey A.E., Lashinger L. M., Hursting S. D. The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci. 2011;1229:45-52. https://doi.org/10.1111/j.1749-6632.2011.06096.x.

20. Merry A., Schouten L., Goldbohm R., van Den Brandt P. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardias: A prospective cohort study. Gut. 2007;56:1503-1511. https://doi.org/10.1136/gut.2006.116665.

21. Singh S., Sharma A. N., Murad M. H., et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2013;11:1399-1412. https://doi.org/10.1016/j.cgh.2013.05.009.

22. El-Serag H., Hashmi A., Garcia J. et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett’s oesophagus: A case-control study. Gut. 2014;63:220-229. https://doi.org/10.1136/gutjnl-2012-304189.

23. Uzel M., Sahiner Z., Filik L. Non-alcoholic fatty liver disease, metabolic syndrome and gastric cancer: Single center experience. J BUON. 2015;20(2):662.

24. Stocks T., Bjørge T., Ulmer H. et al. Metabolic risk score and cancer risk: Pooled analysis of seven cohorts.Int. J. Epidemiol. 2015;44:1353-1363. https://doi.org/10.1093/ije/dyv001.

25. Horiguchi A., Ito K., Sumitomo M. et al. Decreased serum adiponectin levels in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol. 2008;38(2):106-111. https://doi.org/10.1093/jjco/hym158.

26. Rosato V., Bosetti C., Talamini R. et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann. Oncol. 2011;22:2687-2692. https://doi.org/10.1093/annonc/mdr025.

27. Berrino F., Villarini A., Traina A. et al. Metabolic syndrome and breast cancer prognosis. Breast Cancer Res. Treat. 2014;147:159-165. https://doi.org/10.1007/s10549-014-3076-6.

28. Choi W.M., Lee J. H., Yoon J. H. et al. Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. Endocr Relat Cancer. 2014;21(2):343-353. Published 2014 Mar 7. https://doi.org/10.1530/ERC-14-0036.

29. Arase Y., Kobayashi M., Suzuki F. et al. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res. 2012;42(3):264-272. https://doi.org/10.1111/j.1872-034X.2011.00915.x.

30. Gacci M., Russo G., De Nunzio C. et al. Meta-analysis of metabolic syndrome and prostate cancer. Prostate cancer and prostatic diseases. 2017;20:146 10.1038/pcan.2017.1.

31. Tilg H., Moschen A. R. Mechanisms behind the link between obesity and gastrointestinal cancers. Best Pract Res Clin Gastroenterol. 2014;28(4):599-610. https://doi.org/10.1016/j.bpg.2014.07.006.

32. Grimberg A., Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 2000;183(1):1-9. https://doi.org/10.1002/(SICI)1097-4652(200004)183:1<1:: AID-JCP1>3.0.CO;2-J.

33. Chan J.M., Stampfer M. J., Giovannucci E. et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279:563-566.

34. Choi Y.J., Lee D. H., Han K. D., et al. Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men. PLoS One. 2018;13(9): e0201308. Published 2018 Sep 19. https://doi.org/10.1371/journal.pone.0201308.

35. Clements V.K., Long T., Long R., Figley C., Smith D. M.C., Ostrand-Rosenberg S. Frontline Science: High fat diet and leptin promote tumor progression by inducing myeloid-derived suppressor cells. J Leukoc Biol. 2018;103(3):395-407. https://doi.org/10.1002/JLB.4HI0517-210R.

36. Ringel A.E., Drijvers J. M., Baker G. J. et al. Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. Cell. 2020;183(7):1848-1866.e26. https://doi.org/10.1016/j.cell.2020.11.009.

37. Wang Z., Aguilar E. G., Luna J. I. et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019;25(1):141-151. https://doi.org/10.1038/s41591-018-0221-5.

38. Cortellini A., Ricciuti B., Tiseo M. et al. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. J Immunother Cancer. 2020;8(2): e001403. https://doi.org/10.1136/jitc-2020-001403.

39. Kichenadasse G., Miners J. O., Mangoni A. A. et al. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2020;6(4):512-518. https://doi.org/10.1001/jamaoncol.2019.5241.

40. McQuade J.L., Daniel C. R., Hess K. R. et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19(3):310-322. https://doi.org/10.1016/S1470-2045(18)30078-0.

41. Moran C.P., Shanahan F. Gut microbiota and obesity: Role in aetiology and potential therapeutic target. Best Pract. Res. Clin. Gastroenterol. 2014;28:585-597. https://doi.org/10.1016/j.bpg.2014.07.005.

42. Mehal W. Z. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013;10:637-644. https://doi.org/10.1038/nrgastro.2013.146.

43. Louis P., Hold G. L., Flint H. J. The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 2014;12:661-672. https://doi.org/10.1038/nrmicro3344.

44. Schwabe R.F., Greten T. F. Gut microbiome in HCC-Mechanisms, diagnosis and therapy. J Hepatol. 2020;72(2):230-238. https://doi.org/10.1016/j.jhep.2019.08.016.

45. Spruss A., Kanuri G., Wagnerberger S. et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology. 2009;50:1094-1104. https://doi.org/10.1002/hep.23122.

46. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res. 2003;35(11-12):694-704. https://doi.org/10.1055/s-2004-814147.

47. Pérez-Hernández A.I., Catalán V., Gómez-Ambrosi J. et al. Mechanisms linking excess adiposity and carcinogenesis promotion. Front. Endocrinol. 2014;5:65. https://doi.org/10.3389/fendo.2014.00065.

48. Krolevets T.S., Livzan M. A. Clinical and laboratory markers for predicting liver fibrosis in individuals with non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2018;155(7): 43-51. (in Russ.)@@ Кролевец Т. С., Ливзан М. А. Клинико-лабораторные маркеры прогнозирования фиброза печени у лиц с неалкогольной жиро- вой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2018;155(7): 43-51.

49. Livzan M. A., Krolevets T. S., Mozgovoy S. I., Nikolaev N. A., Nelidova A. V. Features of intestinal microbiota disorders in the development of metabolic disorders in non-alcoholic fatty liver disease. Terapevticheskii arkhiv. 2021;93(2):222-227. (In Russ.) https://doi.org/10.26442/00403660.2021.02.200614.@@ Ливзан М. А., Кролевец Т. С., Мозговой С. И., Николаев Н. А., Нелидова А. В. Особенности нарушения кишечной микробиоты в развитии метаболических нарушений при неалкогольной жировой болезни печени. Терапевтический архив. - 2021. - Т. 93. - № 2. - C. 222-227. https://doi.org/10.26442/00403660.2021.02.200614.

50. Endo H., Hosono K., Uchiyama T. et al. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut. 2011;60:1363-1371. https://doi.org/10.1136/gut.2010.235754.

51. Jaffe T., Schwartz B. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways.Int. J. Cancer. 2008;123:2543-2556. https://doi.org/10.1002/ijc.23821.

52. Chandar A.K., Devanna S., Lu C. et al. Association of serum levels of adipokines and insulin with risk of barrett’s esophagus: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2015;13:2241-2255. https://doi.org/10.1016/j.cgh.2015.06.041.

53. Livzan M. A., Lapteva I. V., Krolevets T. S., Kiselev I. E. Features of the course of gastroesophageal reflux disease associated with obesity and overweight. Therapeutic archive. 2016;88(2):21-27. (In Russ.) https://doi.org/10.17116/terarkh201688221-27.@@ Ливзан М. А., Лаптева И. В., Кролевец Т. С., Киселев И. Е. Особенности течения гастроэзофагеальной рефлюксной болезни, ассоциированной с ожирением и избыточной массой тела. Терапевтический архив. 2016;88(2):21-27. https://doi.org/10.17116/terarkh201688221-27.

54. Delort L., Rossary A., Farges M. C. et al. Leptin, adipocytes and breast cancer: Focus on inflammation and anti-tumor immunity. Life Sci. 2015;140:37-48. https://doi.org/10.1016/j.lfs.2015.04.012.

55. Karapanagiotou E.M., Tsochatzis E. A., Dilana K. D. et al. The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer. 2008;61:391-397. https://doi.org/10.1016/j.lungcan.2008.01.018.

56. Tiaka E.K., Manolakis A. C., Kapsoritakis A. N., Potamianos S. P. The implication of adiponectin and resistin in gastrointestinal diseases. Cytokine Growth Factor Rev. 2011;22:109-119. https://doi.org/10.1016/j.cytogfr.2011.04.002.